GOSS
Gossamer Bio Inc

2,977
Mkt Cap
$87.59M
Volume
23.46M
52W High
$3.87
52W Low
$0.3213
PE Ratio
-0.46
GOSS Fundamentals
Price
$0.3449
Prev Close
$0.3732
Open
$0.3777
50D MA
$1.57
Beta
2.21
Avg. Volume
29.92M
EPS (Annual)
-$0.7455
P/B
-0.66
Rev/Employee
$299,203.70
$774.38
Loading...
Loading...
News
all
press releases
Cantor Fitzgerald Reiterates "Neutral" Rating for Gossamer Bio (NASDAQ:GOSS)
Cantor Fitzgerald restated a "neutral" rating on shares of Gossamer Bio in a report on Monday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Q3 EPS Estimates for Gossamer Bio Boosted by HC Wainwright
Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities researchers at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Gossamer Bio in a report issued on...
MarketBeat·2d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer...
PR Newswire·6d ago
News Placeholder
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After...
PR Newswire·7d ago
News Placeholder
Gossamer Bio (NASDAQ:GOSS) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Gossamer Bio (NASDAQ:GOSS - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of...
MarketBeat·7d ago
News Placeholder
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -7.14% and +81.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary...
Business Wire·7d ago
News Placeholder
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·16d ago
News Placeholder
HC Wainwright Lowers Gossamer Bio (NASDAQ:GOSS) Price Target to $5.00
HC Wainwright decreased their price target on Gossamer Bio from $10.00 to $5.00 and set a "buy" rating for the company in a research note on Friday...
MarketBeat·19d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer...
PR Newswire·19d ago
<
1
2
...
>

Latest GOSS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.